WO2002015916A1 - Utilisation d'acides dihydroboswelliques ou d'extraits de boswellia hydrogenes en traitement preventif et/ou therapeutique - Google Patents

Utilisation d'acides dihydroboswelliques ou d'extraits de boswellia hydrogenes en traitement preventif et/ou therapeutique Download PDF

Info

Publication number
WO2002015916A1
WO2002015916A1 PCT/EP2001/009315 EP0109315W WO0215916A1 WO 2002015916 A1 WO2002015916 A1 WO 2002015916A1 EP 0109315 W EP0109315 W EP 0109315W WO 0215916 A1 WO0215916 A1 WO 0215916A1
Authority
WO
WIPO (PCT)
Prior art keywords
derivatives
acids
acid
salts
boswellia
Prior art date
Application number
PCT/EP2001/009315
Other languages
German (de)
English (en)
Inventor
Thomas Gerke
Stefan Müllner
Wolfgang Denuell
Original Assignee
Henkel Kommanditgesellschaft Auf Aktien
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henkel Kommanditgesellschaft Auf Aktien filed Critical Henkel Kommanditgesellschaft Auf Aktien
Priority to AU2001285885A priority Critical patent/AU2001285885A1/en
Publication of WO2002015916A1 publication Critical patent/WO2002015916A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/324—Boswellia, e.g. frankincense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to dihydroboswellic acids and their physiologically acceptable salts, derivatives and salts of derivatives and hydrogenated extracts from Boswellia, processes for their preparation and the use of dihydroboswellic acids, physiologically acceptable salts, derivatives, salts of the derivatives or hydrogenated extracts from Boswellia for prophylactic purposes and / or therapeutic treatment of undesirable physical or mental conditions in humans or animals.
  • Gum resin from Boswellia serrata (Indian frankincense) is known for its aromatic scent as a therapeutic agent in aromatherapy. In this context, it serves in particular to restore the mental balance, especially for depression and mood disorders. From Dt ⁇ soubl 1998; 95: A-30-31 [Issue 1-2] is known to use gum resin from Boswellia serrata Roxb in India as a traditional medicine from Ayurvedic medicine for a number of inflammatory diseases, such as rheumatoid arthritis, osteoarthritis and cervical spondylosis , is used.
  • boswellic acids and other compounds such as essential oils, terpinols, arabinose, xylose, galactose, uronic acids, b-sitosterol and phlobaphene. Tablets made from extracts of this resin are used in India for the treatment of chronic polyarthritic tis manufactured under the trade names Sallaki ® and H15 ® . Boswellia extracts and boswellic acids have anti-inflammatory properties, as has been demonstrated in a large number of animal models.
  • Boswellic acids are also components of the gum resin from Boswellia carterii Birdw., Which was listed as an olibanum in German pharmacopoeias (supplementary volumes DAB 6 and DAB 1). The previously known pharmacological effects of olibanum are described as anti-inflammatory, analgesic, immunosuppressive, hepatoprotective and antimicrobial. Boswellic acids have been shown to have similar properties.
  • Inflammation is characterized by redness, warmth, swelling, pain and impaired organ function. These symptoms are caused by a number of inflammatory mediators.
  • the current treatment of inflammation occurs either through compounds that inhibit prostaglandin synthesis, but not leukotriene synthesis; they are called non-steroidal anti-inflammatory drugs / anti-rheumatic drugs; or by glucocorticoids that inhibit the formation of prostaglandins and leukotrienes.
  • non-steroidal anti-inflammatory drugs / anti-rheumatic drugs or by glucocorticoids that inhibit the formation of prostaglandins and leukotrienes.
  • both categories of these anti-inflammatory drugs are associated with a whole series of sometimes serious side effects. This applies in particular to the chronic use of glucocorticoids.
  • Prostaglandins and leukotrienes are formed via the so-called arachidonic acid cascade.
  • a concentration-dependent inhibitory effect of boswellic acids, in particular acetyl-boswellic acids, on the formation of leukotrienes and other 5-lipoxygenase products is known from the abovementioned publication.
  • IC50 1.5 ⁇ M
  • boswellic acids inhibit the proliferation of tumor cells such as HL60 and CCRF-CEM gliobastoma cells and melanoma cell in vitro, but in considerably higher concentrations.
  • Leukotrienes have a number of effects, most of which are involved in inflammation. However, broncho-constrictive effects have also been described. There are a large number of chronic inflammatory diseases in which an increased leukotriene production is considered to be partly responsible for the maintenance of the chronic inflammation. These diseases include ulcerative colitis, Crohn's disease, bronchial asthma, rheumatoid arthritis and others.
  • DE-A-42 01 903 and EP-A-0 552 657 disclose the use of pure boswellic acid, a physiologically acceptable salt, a derivative, a salt of the derivative or a plant preparation containing boswellic acid for prophylaxis and / or control of inflammatory processes that are caused by increased leukotriene formation, are known in human or veterinary medicine.
  • WO 97/07796 describes the use of pure boswellic acid, a physiologically acceptable salt, a derivative, a salt of the derivative or a plant preparation containing boswellic acid for the prophylaxis and / or combating of diseases caused by increased leucocyte elastase - or piasmin activity are caused or which can be treated by inhibition of normal leukocyte elastase or piasmin activity, are known in human or veterinary medicine.
  • the resin from boswellia species, boswellic acid and their derivatives are only slightly toxic, but side effects (gastrointestinal complaints, allergic reactions) have also been described when used as directed (Dt ⁇ chtbl 1998; 95: A-30-31 [Issue 1-2]) ).
  • the object of the present invention is to provide a substance which can be used for the preventive or therapeutic treatment of undesirable physical or mental conditions, in particular the abovementioned diseases, while avoiding as far as possible the disadvantages known from the prior art.
  • Another object of the present invention is the use of dihydroboswellic acids, physiologically acceptable salts of dihydroboswellic acids or hydrogenated extracts from Boswellia for the prophylactic and / or therapeutic treatment of undesirable physical or mental conditions in humans or animals.
  • dihydroboswellic acids includes compounds of the formulas A and B, in particular those with the following led substituents understood:
  • R H 11-keto-ß-dihydroboswellic acid
  • R acetyl acetyl-11-keto-ß-dihydroboswellic acid
  • R formyl formyl-11-keto-ß-dihydroboswellic acid
  • R H: ⁇ -dihydroboswellic acid
  • R acetyl: acetyl- ⁇ -dihydroboswellic acid
  • R formyl: formyl- ⁇ -dihydroboswellic acid
  • the sodium, potassium, ammonium or calcium salts can be used as physiologically acceptable salts of dihydroboswellic acid.
  • dihydroboswellic acid lower alkyl esters obtained by esterifying the carboxyl group with a C 1 -C 6 -alcohol, preferably the methyl ester, or esters obtained by esterifying the hydroxyl group obtained with a physiologically compatible carboxylic acid can be used.
  • Preferred derivatives are ⁇ -dihydroboswellic acid acetate, ⁇ -dihydroboswellic acid formate, ⁇ -dihydroboswellic acid methyl ester, acetyl- ⁇ -dihydroboswellic acid, acetyl-11-keto- ⁇ -dihydroboswellic acid and 11-keto- ⁇ -dihydroboswellic acid.
  • Boswellia Plants which contain boswellic acid (syn .: boswellic acid) and from which extracts can be obtained for the subsequent hydrogenation are, for example: Boswellia (serrata, papyrifera, frereana, carteri, thurifera, glabra, bhaw-dajiana, oblongata, socotrana and other representatives of these Family).
  • the compounds which can be used according to the invention can be obtained by hydrogenation, preferably by catalytic hydrogenation of Boswellia resin or Boswellic acids (one or different) or physiologically acceptable salts, derivatives or salts of the derivatives of these acids.
  • the present invention therefore furthermore relates to a process for the preparation of dihydroboswellic acids, their physiologically acceptable salts, derivatives, salts of the derivatives or hydrogenated extracts from Boswellia, using Boswellia resin or Boswellic acids (one or different) or physiologically acceptable salts, derivatives or Dissolves salts of the derivatives of these acids in a suitable solvent and hydrogenates the dissolved resin or the dissolved acids, salts, derivatives or salts of the derivatives in the presence of a hydrogenation catalyst.
  • Suitable solvents are, for example, alkanols, in particular ethanol, and cyclohexane.
  • the hydrogenation is carried out in a manner known to those skilled in the art, preferably in such a way that the carbon-carbon double bond of the boswellic acid backbone is selectively hydrogenated.
  • the hydrogenation can take place under heterogeneous or under homogeneous catalysis.
  • a catalyst which is insoluble in the reaction medium and on the surface of which the actual catalysis is brought about by adsorption and desorption equilibria of the compound to be hydrogenated and the hydrogen.
  • Suitable catalysts are noble metals such as Pt, Pd and Rh or transition metals such as Mo, W, Cr, but especially Fe, Co and.
  • Ni either individually or in a mixture or to increase the activity and stability on supports such as activated carbon, aluminum oxide or diatomaceous earth. Raney nickel, Pd bound to activated carbon, metallic Pt and platinum and zinc oxide can be used in particular.
  • catalysts are soluble in the reaction medium.
  • Suitable catalysts for homogeneous catalysis are transition metal complexes, for example the well-known Wilkinson catalyst [chlorotris (triphenylphosphine) rhodium].
  • the hydrogenation is carried out with supported catalysts in a heterogeneous system, e.g. in a fixed bed or in a fluidized bed or in the so-called trickle phase.
  • the hydrogenation conditions can be varied in a known manner by the person skilled in the art.
  • the hydrogenation temperature can be in the range from approximately 0 ° C. to approximately 275 ° C., in particular in the range from approximately 80 ° C. to approximately 120 ° C.
  • the pressure can be in the range from normal pressure up to about 300 bar, preferably in the range from about 150 bar to about 250 bar.
  • the undesirable physical or mental conditions to be treated in the context of the use according to the invention are preferably selected from somatic, psychosomatic and psychological disorders in humans or animals; especially among inflammatory processes caused by increased leukotriene formation and especially under inflammatory joint diseases, epidermal lesions (psoriasis), allergic and chronic asthma, endotoxin shock, inflammatory bowel diseases (ulcerative colitis, Crohn's disease) or chronic hepatitis.
  • Further undesirable physical conditions to be treated in the context of the use according to the invention are preferably selected from those which are caused by increased leukocyte elastase or piasmin activity or which can be treated by inhibiting normal leukocyte elastase or piasmin activity; especially those with pulmonary emphysema, acute respiratory distress syndrome, shock lung, cystic fibrosis (cystic fibrosis), chronic bronchitis, glomerulonephritis and rheumatoid arthritis, which are caused by increased leukocyte elastase activity, and tumors and tumor metastases, which are caused by increased piasmina.
  • the use according to the invention takes the form of tablets, dragées, capsules, solutions, emulsions, ointments, creams, inhalation preparations, aerosols or suppositories.
  • Another object of the present invention is the use of dihydroboswellic acids, their physiologically acceptable salts, derivatives, salts of derivatives or hydrogenated extracts from Boswellia for the manufacture of a medicament for the prophylactic and / or therapeutic treatment of undesirable physical or mental conditions in humans or animals, especially for the treatment of the conditions and diseases mentioned above.
  • the use according to the invention of dihydroboswellic acids, their physiologically acceptable salts, derivatives, salts of the derivatives or hydrogenated extracts from Boswellia for the treatment of undesirable conditions or for the production of a medicament can take place together with other chemically pure medicinal substances and / or herbal medicinal products. Suitable medicinal substances or medicinal products are listed in DE-A-42 01 903, to which reference is hereby made in full.
  • Undecylenic acid polyoxyethylene lauryl ether sulfate, etretinate, zinc oxide, urea, lactic acid.
  • Nonsteroidal anti-inflammatory drugs pyrazole derivatives: Azapropazon, Bumadizon, Famprofazon, Mofebutazon, Nifenazon, Oxyphenbutazon, Phenylbutazon, Pyrazinobutazon.
  • Acrylic acetic acid derivatives and indole derivatives acemetacin, bufexamac, diclofenac, indomethacin, lonazolac, proglumetacin, tolmetin.
  • Anthranilic acid derivatives flufenamic acid, mefenamic acid, niflumic acid.
  • Naproxen, piroxicam, pirprofen, tiaprofenic acid Naproxen, piroxicam, pirprofen, tiaprofenic acid.
  • Oxicame tenoxicam
  • Dihydroboswellic acid and hydrogenated extracts from Boswellia have an odor that is clearly distinguishable from that of their unhydrogenated starting compounds, but this is similarly aromatic and pleasant as that of the unhydrogenated starting compounds.
  • dihydroboswellic acid and hydrogenated extracts from Boswellia can also be used for aromatherapy.
  • they because of their pleasant smell and the anti-inflammatory effect described above, they can be used as valuable components of cosmetics and personal care products.
  • Another object of the present invention is therefore the use of dihydroboswellic acids, their physiologically acceptable salts, derivatives, salts of the derivatives or hydrogenated extracts from Boswellia in or for the production of hand washing detergents, hand dishwashing detergents, cosmetics or personal care products.
  • the present invention furthermore relates to medicaments, personal care products, cosmetics, hand washing detergents and dishwashing detergents which contain dihydroboswellic acids, their physiologically acceptable salts, derivatives, salts of the derivatives or hydrogenated extracts from Boswellia.
  • the cosmetics and personal care products according to the invention can be used as auxiliaries and additives, mild surfactants, Oil bodies, emulsifiers, superfatting agents, pearlescent waxes, consistency enhancers, thickeners, polymers, silicone compounds, fats, waxes, stabilizers, biogenic agents, deodorants, antiperspirants rantien, anti-dandruff agents, film formers, swelling agents, UV light protection factors, antioxidants, hydrotropes, preservatives, insect repellents, self-tanners, solubilizers, perfume oils, dyes and the like contain.
  • mild surfactants Oil bodies, emulsifiers, superfatting agents, pearlescent waxes, consistency enhancers, thickeners, polymers, silicone compounds, fats, waxes, stabilizers, biogenic agents, deodorants, antiperspirants rantien, anti-dandruff agents, film formers, swelling agents, UV light protection factors, antioxidants, hydrotropes, preservatives, insect repellent
  • Suitable mild, i.e. surfactants which are particularly compatible with the skin are fatty alcohol polyglycol ether sulfates, monoglyceride sulfates, mono- and / or dialkyl sulfosuccinates, fatty acid isethionates, fatty acid sarcosinates, fatty acid tauids, fatty acid glutamates, ⁇ -olefin sulfonates, ether carboxylic acids, alkyl oligogluamide amides, fatty acids / fatty acids / protein amides, fatty acids / fatty acid amides and fatty acids, fatty acids / fatty acid amides / fatty acids, fatty acids / fatty acid fatty acids, and / or fatty acid fatty acids, fatty acids / fatty acid fatty acids, fatty acid fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty
  • Guerbet alcohols based on fatty alcohols having 6 to 18, preferably 8 to 10 carbon atoms, esters of linear C 6 -C 22 fatty acids with linear C6-C 22 fatty alcohols, esters of branched C 6 -C ⁇ 3 - are, for example, oil bodies.
  • Carboxylic acids with linear C 6 -C 22 fatty alcohols such as, for example, myristyl myristate, myristyl palmitate, myristyl stearate, myristyl isostearate, myristyl oleate, myristyl behenate, myristyl erucate, cetyl myristate, cetyl palmitate, cetyl stearate, cetyl paletate, cetyl paletate - did stearylstearate, Stearylisostearat, stearyl, stearyl, Stearyleru- cat, isostearyl, isostearyl, Isostearylstearat, isostearyl isostearate, Isostearyloleat, isostearyl behenate, Isostearyloleat, oleyl, oleyl palmitate, oleyl stearate, oleyl isostearate, oleate
  • esters of linear C 6 -C 22 fatty acids with branched are suitable
  • Alcohols especially 2-ethylhexanol, esters of hydroxycarboxylic acids with linear or branched C 6 -C 22 fatty alcohols, especially dioctyl malates,
  • Esters of linear and / or branched fatty acids with polyhydric alcohol len such as propylene glycol, dimer diol or trimer triol
  • polyhydric alcohol len such as propylene glycol, dimer diol or trimer triol
  • Guerbet alcohols triglycerides based on C ⁇ -Cio fatty acids, liquid mono- / di- / triglyceride mixtures based on C 6 -C 8 fatty acids, esters of C6-C22 - Fatty alcohols and / or Guerbet alcohols with aromatic carboxylic acids, especially benzoic acid, esters of C 2 -Ci 2 dicarboxylic acids with linear or branched alcohols with 1 to 22 carbon atoms or polyols with 2 to 10 carbon atoms and 2 to 6 hydroxyl groups, vegetable oils, branched primary Alcohols, substituted cyclohexanes, linear and branched C 6 -C 22 fatty alcohol carbonates, Guerbet
  • Finsolv ® TN linear or branched, symmetrical or asymmetrical dialkyl ethers 6 to 22 carbon atoms per alkyl group, ring opening products of epoxidized fatty acid esters with polyols, silicone oils and / or aliphatic or naphthenic Hydrocarbons such as B. squalane, squalene or dialkylcyclohexanes.
  • Suitable emulsifiers are nonionic surfactants from at least one of the following groups:
  • Polyglycerol pentaerythritol, dipentaerythritol, sugar alcohols (e.g. sorbitol), alkyl glucosides (e.g. methyl glucoside, butyl glucoside, lauryl glucoside) and polyglucosides (e.g. cellulose);
  • sugar alcohols e.g. sorbitol
  • alkyl glucosides e.g. methyl glucoside, butyl glucoside, lauryl glucoside
  • polyglucosides e.g. cellulose
  • adducts of ethylene oxide and / or of propylene oxide with fatty alcohols, fatty acids, alkylphenols, glycerol mono- and diesters, and sorbitan mono- and diesters with fatty acids or with castor oil are known, commercially available products.
  • glycoside residue both monoglycosides in which a cyclic sugar residue is glycosidically bonded to the fatty alcohol and oligomeric glycosides with a degree of oligomerization of up to about 8 are suitable.
  • the degree of oligomerization is a statistical mean value which is based on a homolog distribution customary for such technical products.
  • polyglycerol esters are polyglyceryl-2 dipolyhydroxystearate (Dehymuls ® PGPH), polyglycerol-3-diisostearate (Lameform ® TGI), polyglyceryl-4 isostearate (Isolan ® Gl 34), polyglyceryl-3 oleates, diisostearoyl polyglyceryl 3 diisostearates (Isolan ® PDI), polyglyceryl-3 methyl glucose distearate (Tego Care ® 450), polyglyceryl-3 beeswax (Cera Bellina ® ), polyglyceryl-4 caprate (polyglycerol caprate T2010 / 90), polyglyceryl-3 cetyl ether ( Chimexane ® NL), Polyglyceryl-3 Distearate (Cremophor ® GS 32) and Polyglyceryl Polyricinoleate (Admul ® WOL 1403), Polyglyceryl-2
  • Zwitterionic surfactants can also be used as emulsifiers.
  • Zwitterionic surfactants are surface-active compounds that contain at least one quaternary ammonium group and at least one carboxylate and one sulfonate group in the molecule.
  • Particularly suitable zwitterionic surfactants are the so-called betaines such as the N-alkyl-N, N-dimethylammonium glycinate, for example the coconut alkyldimethylammonium glycinate, N-acylaminopropyl-N, N-dimethylammonium glycinate, for example the coconut acylaminopropyldimethylammonium glycinate, and 2-alkyl-3-carboxylm -hydroxyethylimidazolines each having 8 to 18 carbon atoms in the alkyl or acyl group and the cocoacylaminoethylhydroxyethyl- carboxymethylglycinat.
  • betaines such as the N-alkyl-N, N-dimethylammonium glycinate, for example the coconut alkyldimethylammonium glycinate, N-acylaminopropyl-N, N-dimethylammonium glycinate
  • Suitable emulsifiers are ampholytic surfactants.
  • Ampholytic surfactants are surface-active compounds which, in addition to a Cs / is alkyl or acyl group, contain at least one free amino group and at least one -COOH or -SOsH group in the molecule and are capable of forming internal salts.
  • ampholytic surfactants are N-alkylglycines, N-alkylpropionic acids, N-alkylaminobutyric acids, N-alkyliminodipropionic acids, N-hydroxyethyl-N-alkylamidopropylglycines, N-alkyltaurines, N-alkylsarcosines, 2-alkylaminopropionic acids and alkylaminoacetic acids each about 8 to 18 carbon atoms in the alkyl group.
  • Particularly preferred ampholytic surfactants are N-coconut alkyl aminopropionate, coconut acylaminoethyl aminopropionate and C12 / 18 acyl sarcosine.
  • quaternary emulsifiers are also suitable, those of the esterquat type, preferably methyl-quaternized difatty acid triethanolamine ester salts, being particularly preferred.
  • Substances such as, for example, lanolin and lecithin and polyethoxylated or acylated lanolin and lecithin derivatives, polyol fatty acid esters, monoglycerides and fatty acid alkanolamides can be used as superfatting agents, the latter simultaneously serving as foam stabilizers.
  • Pearlescent waxes that can be used are, for example: alkylene glycol esters, especially ethylene glycol distearate; Fatty acid alkanolamides, especially coconut fatty acid diethanolamide; Partial glycerides, especially stearic acid monoglyceride; Esters of polyvalent, optionally hydroxy-substituted carboxylic acids with fatty alcohols having 6 to 22 carbon atoms, especially long-chain esters of tartaric acid; Fatty substances, such as, for example, fatty alcohols, fatty ketones, fatty aldehydes, fatty ethers and fatty carbonates, which have a total of at least 24 carbon atoms, especially lauron and distearyl ether; Fatty acids such as stearic acid, hydroxystearic acid or behenic acid, ring opening products of olefin epoxides with 12 to 22 carbon atoms with fatty alcohols with 12 to 22 carbon atoms and / or polyols with 2 to 15
  • the main consistency agents are fatty alcohols or hydroxy fatty alcohols with 12 to 22 and preferably 16 to 18 carbon atoms and, in addition, partial glycerides, fatty acids or hydroxy fatty acids.
  • a combination of these substances with alkyl oligoglucosides and / or fatty acid N-methylglucamides of the same chain length and / or polyglycerol poly-12-hydroxystearates is preferred.
  • Suitable thickeners are, for example, Aerosil types (hydrophilic silicas), polysaccharides, in particular xanthan gum, guar guar, agar agar, alginates and tyloses, carboxymethyl cellulose and hydroxyethyl cellulose, and also higher molecular weight polyethylene glycol mono- and diesters of fatty acids, polyacrylates (eg carbopols) ® from Goodrich or Synthalene ® from Sigma), polyacrylamides, polyvinyl alcohol and polyvinylpyrrolidone, surfactants such as ethoxylated fatty acid glycerides, esters of fatty acids with polyols such as pentaerythritol or trimethylolpropane, fatty alcohol ethoxylates with a narrow homolog distribution or alkyl oligoglucosides and electrolytes such as sodium chloride and ammonium chloride.
  • Aerosil types hydrophilic silicas
  • Suitable cationic polymers are, for example, cationic cellulose derivatives, such as a quaternized hydroxyethyl cellulose, which is available under the name Polymer JR 400® from Amerchol, cationic starch, copolymers of diallylammonium salts and acrylamides, quaternized vinylpyrrolidone / vinylimidazole polymers , such as Luviquat® (BASF), condensation products of polyglycols and amines, quaternized collagen polypeptides, such as, for example, lauryldimonium hydroxypropyl hydrolyzed collagen (Lamequat®L / Grünau), quaternized wheat polypeptides, polyethyleneimine, cationic silicone polymers, such as, for example, amidomethicones and copolymers of the professiontes Dimethylaminohydroxypropyldiethylenetriamine (Cartaretine® / Sandoz), copolymers of acrylic acid with dimethyldiallylammoni
  • Anionic, zwitterionic, amphoteric and nonionic polymers include, for example, vinyl acetate / crotonic acid copolymers, vinyl pyrrolidone / vinyl acrylate copolymers, vinyl acetate / butyl maleate / isobomylacrylate copolymers, methyl vinyl ether / maleic anhydride copolymers and their polyols and uncrosslinked polyols and their esters , Acrylamidopro- pyltrimethylammoniumchlorid / acrylate copolymers, octylacrylamide / acrylate Methylmeth- / tert.Butylaminoethylmethacrylat / 2 Hydroxyproyl methacrylate copolymers, polyvinylpyrrolidone, vinylpyrrolidone / vinyl acetate copolymers, vinylpyrrolidone / dimethylaminoethyl methacryl
  • Suitable silicone compounds are, for example, dimethylpolysiloxanes, methylphenylpolysiloxanes, cyclic silicones and amino, fatty acid, alcohol, polyether, epoxy, fluorine, glycoside and / or alkyl-modified silicone compounds, which can be both liquid and resinous at room temperature.
  • Simethicones which are mixtures of dimethicones with an average chain length of 200 to 300 dimethylsiloxane units and hydrogenated silicates, are also suitable.
  • a detailed overview of suitable volatile silicones can also be found by Todd et al. in Cosm.Toil. 91, 27 (1976).
  • fats are glycerides
  • waxes include natural waxes such as candelilla wax, carnauba wax, Japanese wax, espresso grass wax, cork wax, guaruma wax, rice-germ oil wax, sugar cane wax, ouricury wax, montan wax, beeswax, shellac wax, walnut, lanolin ( Wool wax), pretzel fat, ceresin, ozokerite (earth wax), petrolatum, paraffin waxes, micro waxes; chemically modified waxes (hard waxes), such as montan ester waxes, Sasol waxes, hydrogenated jojoba waxes and synthetic waxes, such as polyalkylene waxes and polyethylene glycol waxes, are possible.
  • natural waxes such as candelilla wax, carnauba wax, Japanese wax, espresso grass wax, cork wax, guaruma wax, rice-germ oil wax, sugar cane wax, ouricury wax, montan wax, beeswa
  • Metal salts of fatty acids such as e.g. Magnesium, aluminum and / or zinc stearate or ricinoleate are used.
  • Biogenic active substances are, for example, tocopherol, tocopherol acetate, tocopherol palmitate, ascorbic acid, deoxyribonucleic acid, retinol, bisabolol, allantoin, phytantriol, panthenol, AHA acids, amino acids, ceramides, pseudo doceramides, essential oils, plant extracts and vitamin complexes.
  • Cosmetic deodorants counteract, mask or eliminate body odors.
  • Body odors arise from the action of skin bacteria on apocrine sweat, whereby unpleasant smelling breakdown products are formed. Accordingly, deodorants contain active substances which act as germ-inhibiting agents, enzyme inhibitors, odor absorbers or odor maskers.
  • all substances which are effective against gram-positive bacteria are suitable, such as B. 4-hydroxybenzoic acid and its salts and esters, N- (4-chlorophenyl) -N ' - (3,4 dichlorophenyl) urea, 2,4,4'-trichloro-2 ' - hydroxydiphenyl ether (triclosan), 4-chloro-3,5-dimethylphenol, 2,2 ' -methylene bis (6-bromo-4-chlorophenol), 3-methyl-4- (1-methylethyl) phenol, 2-benzyl 4-chlorophenol, 3- (4-chlorophenoxy) -1, 2-propanediol, 3-iodo-2-propynylbutylcarbamate, chlorhexidine, 3,4,4'-trichlorocarbanilide (TTC), antibacterial fragrances, thymol, thyme oil, eugen
  • Enzyme inhibitors can also be added to the cosmetics according to the invention.
  • Suitable enzyme inhibitors are, for example, esterase inhibitors. These are preferably trialkyl such as trimethyl citrate, tripropyl, triisopropyl, tributyl citrate and especially triethyl citrate (Hydagen® ® CAT, Fa. Cognis, Dusseldorf / FRG). The substances inhibit enzyme activity and thereby reduce odor.
  • esterase inhibitors include sterol sulfates or phosphates, such as, for example, lanosterol, cholesterol, campesteric, stigmasterol and sitosterol sulfate or phosphate, dicarboxylic acids and their esters, such as, for example, glutaric acid, giutaric acid monoethyl ester, glutaric acid diethyl ester, adipic acid, Monoethyl adipate, diethyl adipate, malonic acid and diethyl malonate, hydroxycarboxylic acids and their esters such as, for example, citric acid, malic acid, tartaric acid or tartaric acid diethyl ester, and zinc glycinate.
  • dicarboxylic acids and their esters such as, for example, glutaric acid, giutaric acid monoethyl ester, glutaric acid diethyl ester, adipic acid, Monoethyl adipate, diethyl
  • Suitable odor absorbers are substances that absorb odor-forming compounds and can retain them to a large extent. They lower the partial pressure of the individual components and thus also reduce their speed of propagation. It is important that perfumes must remain unaffected. Odor absorbers are not effective against bacteria. They contain, for example, a complex zinc salt of ricinoleic acid as a main component or special, largely odorless fragrances that are known to the person skilled in the art "Fixateurs" are known, such as. B. extracts of Labdanum or Styrax or certain abietic acid derivatives.
  • Fragrance agents or perfume oils act as odor maskers and, in addition to their function as odor maskers, give the deodorants their respective fragrance.
  • Perfume oils include mixtures of natural and synthetic fragrances. Natural fragrances are extracts of flowers (lily, lavender, roses, jasmine, neroli, ylang-ylang), stems and leaves (geranium, patchouli, petitgrain), fruits (anise, coriander, caraway, juniper), fruit bowls (bergamot, Lemon, oranges), roots (mace, angelica, celery, cardamom, costus, iris, calmus), woods (pine, sandal, guaiac, cedar, rosewood), herbs and grasses (tarragon, lemongrass, sage, thyme ), Needles and twigs (spruce, fir, pine, mountain pine), resins and balsams (galbanum, elemi, benzoin, myrrh, olibanum, opoponax).
  • Typical synthetic fragrance compounds are products of the ester, ether, aldehyde, ketone, alcohol and hydrocarbon type. Fragrance compounds of the ester type are, for example, benzyl acetate, phenoxyethyl isobutyrate, p-tert-butylcyclohexyl acetate, linalyl acetate, dimethylbenzylcarbinylacetate, phenylethyl acetate, linalyl benzoate, benzyl formate, ethyl methylphenyl glycinate, allyl cyclohexylalylpionyl xylpropylyl allyl propyl pylyl allyl propionate.
  • the ethers include, for example, benzyl ethyl ether
  • the aldehydes include, for example, the linear alkanals with 8 to 18 carbon atoms, citral, citronellal, citronellyloxyacetaldehyde, cyclamaldehyde, hydroxycitronellal, lilial and bourgeonal
  • the ketones include, for example, the ionones, o-isomethyl ionone and methyl cedryl ketone the alcohols anethole, citronellol, eugenol, isoeugenol, geraniol, linalool, phenylethyl alcohol and terpineol
  • the hydrocarbons mainly include the terpenes and balsams.
  • fragrance oils which are mostly used as aroma components
  • perfume oils for example sage oil, chamomile oil, clove oil, melissa oil, mint oil, cinnamon leaf oil, linden blossom oil, juniper berry oil, vetiver oil, oliban oil, galbanum oil, labolanum oil and lavandin oil.
  • Antiperspirants reduce sweat formation by influencing the activity of the eccrine sweat glands and thus counteract armpit wetness and body odor.
  • Aqueous or anhydrous formulations of antiperspirants typically contain the following ingredients:
  • auxiliaries such.
  • non-aqueous solvents such.
  • ethanol, propylene glycol and / or glycerin As ethanol, propylene glycol and / or glycerin.
  • Salts of are particularly suitable as astringent antiperspirant active ingredients
  • Such suitable antiperspirant active ingredients are, for example, aluminum chloride, aluminum chlorohydrate, aluminum dichlorohydrate, aluminum sesquichlorohydrate and their composite compounds z.
  • B. with amino acids such as glycine amino acids
  • conventional oil-soluble and water-soluble auxiliaries can be present in smaller amounts in antiperspirants. Examples of such oil-soluble auxiliaries are:
  • water-soluble additives are e.g. Preservatives, water-soluble fragrances, pH adjusters, e.g. Buffer mixtures, water soluble thickeners, e.g. water-soluble natural or synthetic polymers such as e.g. Xanthan gum, hydroxyethyl cellulose, polyvinyl pyrrolidone or high molecular weight polyethylene oxides.
  • Climbazole, octopirox and zinc pyrethione can be used as antidandruff agents.
  • Common film formers are, for example, chitosan, microcrystalline chitosan, quaternized chitosan, polyvinylpyrrolidone, vinylpyrrolidone-vinyl acetate copolymers, polymers of the acrylic acid series, quaternary cellulose derivatives, collagen, hyaluronic acid or its salts and similar compounds.
  • UV light protection factors are understood to mean, for example, organic substances (light protection filters) which are liquid or crystalline at room temperature and are able to absorb ultraviolet rays and release the absorbed energy in the form of longer-wave radiation, for example heat.
  • UVB filters can be oil-soluble or water-soluble. Examples of oil-soluble substances are:
  • 3-benzylidene camphor or 3-benzylidene norcampher and its derivatives e.g. 3- (4-methylbenzylidene) camphor as described in EP 0693471 B1;
  • 4-aminobenzoic acid derivatives preferably 2-ethylhexyl 4-dimethylamino) benzoate, 2-octyl 4- (dimethylamino) benzoate and amyl 4- (dimethylamino) benzoate;
  • esters of cinnamic acid preferably 2-ethylhexyl 4-methoxycinnamate, propyl 4-methoxycinnamate, isoamyl 4-methoxycinnamate, 2-cyano-
  • esters of salicylic acid preferably salicylic acid 2-ethylhexyl ester, salicylic acid 4-isopropylbenzyl ester, salicylic acid homomethyl ester;
  • benzophenone preferably 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone;
  • esters of benzalmalonic acid preferably di-2-ethylhexyl 4-methoxybenzmalonate
  • Triazine derivatives e.g. 2,4,6-trianilino- (p-carbo-2'-ethyl-1'-hexyloxy) -1, 3,5-triazine and octyl triazone, as described in EP 0818450 A1 or dioctyl butamido triazone (Uvasorb® HEB );
  • Propane-1,3-dione e.g. 1- (4-tert-butylphenyl) -3-4'methoxyphenyl) propane-1,3-dione;
  • Possible water-soluble substances are: • 2-phenylbenzimidazole-5-sulfonic acid and its alkali, alkaline earth, ammonium, alkylammonium, alkanolammonium and glucammonium salts;
  • Sulfonic acid derivatives of 3-benzylidene camphor e.g. 4- (2-oxo-3-bornylidene methyl) benzenesulfonic acid and 2-methyl-5- (2-oxo-3-bornylidene) sulfonic acid and their salts.
  • UV-A filters Derivatives of benzoylmethane, such as 1- (4'-tert-butylphenyl) -3- (4'-methoxyphenyl) propane-1,3-dione, 4-tert, are particularly suitable as typical UV-A filters.
  • -Butyl-4'-methoxydibenzoylmethane (Parsol 1789), 1-phenyl-3- (4'-isopropylphenyl) -propane-1, 3-dione and enamine compounds as described in DE 19712033 A1 (BASF).
  • the UV-A and UV-B filters can of course also be used in mixtures.
  • insoluble light protection pigments namely finely dispersed metal oxides or salts
  • suitable metal oxides are, in particular, zinc oxide and titanium dioxide and, in addition, oxides of iron, zirconium, silicon, manganese, aluminum and cerium and mixtures thereof.
  • Silicates (talc), barium sulfate or zinc stearate can be used as salts.
  • the oxides and salts are used in the form of the pigments for skin-care and skin-protecting emulsions and decorative cosmetics.
  • the particles should have an average diameter of less than 100 nm, preferably between 5 and 50 nm and in particular between 15 and 30 nm.
  • the pigments can also be surface-treated, ie hydrophilized or hydrophobicized.
  • Typical examples are coated titanium dioxides, such as titanium dioxide T 805 (Degussa) or Eusoiex® T2000 (Merck).
  • the main hydrophobic coating agents used are silicones and especially trialkoxy octylsilane or Simethicone in question. So-called micro- or nanopigments are preferably used in sunscreens. Micronized zinc oxide is preferably used. Further suitable UV light protection filters can be found in the overview by P.Finkel in S ⁇ FW-Journal 122, 543 (1996).
  • secondary light stabilizers of the antioxidant type can also be used, which interrupt the photochemical reaction chain which is triggered when UV radiation penetrates the skin.
  • Typical examples are amino acids (e.g. glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (e.g. urocanic acid) and their derivatives, peptides such as D, L-carnosine, D-carnosine, L-carnosine and their derivatives (e.g.
  • Carotenoids eg ⁇ -carotene, ⁇ -carotene, lycopene
  • carbotenoids eg ⁇ -carotene, ⁇ -carotene, lycopene
  • chlorogenic acid and their derivatives lipoic acid and their derivatives (eg dihydrolipoic acid), aurothioglucose, propylthiouracil and other thiols (eg thioredoxin, glutathione, Cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, ⁇ -linoleyl, cholesteryl and glyceryl esters ) as well as their salts, dilaurylthiodipropionate, distearylthiodipropionate, thiodipropionic acid and their derivatives (est
  • butioninsulfoximines homocysteine sulfoximine, butioninsulfones, penta-, hexa-, hepa-, hepa- tathioninsulfoximin) in very g achieve tolerable dosages (e.g. pmol to ⁇ mol / kg), also (metal) chelators (e.g. ⁇ -hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin), ⁇ -hydroxy acids (e.g.
  • citric acid citric acid, lactic acid, malic acid
  • humic acid bile acid, bile extracts, bilirubin , Biliverdin, EDTA, EGTA and their derivatives
  • unsaturated fatty acids and their derivatives e.g. ⁇ -linolenic acid, linoleic acid, oleic acid
  • folic acid and their derivatives ubiquinone and ubiquinol and their derivatives
  • vitamin C and derivatives e.g. ascorbyl palmitate, Mg ascorbyl phosphate, ascorbyl acetate
  • tocopherols and derivatives e.g.
  • vitamin E acetate
  • vitamin A and derivatives vitamin A palmitate
  • Hydrotropes such as ethanol, isopropyl alcohol or polyols can also be used to improve the flow behavior.
  • Polyols that come into consideration here preferably have 2 to 15 carbon atoms and at least two hydroxyl groups.
  • the polyols can also contain further functional groups, in particular amino groups, or be modified with nitrogen. Typical examples are
  • Alkylene glycols such as, for example, ethylene glycol, diethylene glycol, propylene glycol, butylene glycol, hexylene glycol and polyethylene glycols with an average molecular weight of 100 to 1,000 daltons;
  • Methyl compounds such as, in particular, trimethylolethane, trimethylolpropane, trimethylolbutane, pentaerythritol and dipentaerythritol;
  • Lower alkyl glucosides in particular those with 1 to 8 carbons in the alkyl radical, such as methyl and butyl glucoside;
  • Sugar alcohols with 5 to 12 carbon atoms such as, for example, sorbitol or mannitol
  • Sugar with 5 to 12 carbon atoms such as, for example, glucose or sucrose
  • Dialcohol amines such as diethanolamine or 2-amino-1, 3-propanediol.
  • Suitable preservatives are, for example, phenoxyethanol, formaldehyde solution, parabens, pentanediol or sorbic acid and the other classes of substances listed in Appendix 6, Parts A and B of the Cosmetics Ordinance.
  • N, N-diethyl-m-toluamide, 1, 2-pentanediol or ethyl butylacetylaminopropionate are suitable as insect repellents, and dihydroxyacetone is suitable as a self-tanning agent.
  • the dyes which can be used are the substances which are suitable and approved for cosmetic purposes, as compiled, for example, in the publication "Cosmetic Dyes” by the Dye Commission of the German Research Foundation, Verlag Chemie, Weinheim, 1984, pp. 81-106. These dyes are usually used in concentrations of 0.001 to 0.1% by weight, based on the mixture as a whole.
  • the total proportion of auxiliaries and additives can be 1 to 50, preferably 5 to 40,% by weight, based on the composition.
  • the agents can be produced by customary cold or hot processes; the phase inversion temperature method is preferably used.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des acides dihydroboswelliques, leurs sels, leurs dérivés et les sels de ces dérivés physiologiquement tolérables et des extraits de Boswellia hydrogénés, ainsi que leur procédé de production. L'invention concerne également l'utilisation d'acides dihydroboswelliques, de leurs sels, leurs dérivés et sels de ces dérivés physiologiquement tolérables, ou d'extraits de Boswellia hydrogénés pour le traitement préventif et/ou thérapeutique d'états physiques ou psychiques non souhaités chez l'homme ou chez l'animal.
PCT/EP2001/009315 2000-08-22 2001-08-11 Utilisation d'acides dihydroboswelliques ou d'extraits de boswellia hydrogenes en traitement preventif et/ou therapeutique WO2002015916A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001285885A AU2001285885A1 (en) 2000-08-22 2001-08-11 Use of dihydroboswellic acids or hydrogenated extracts of boswellia for prophylactic and/or therapeutic treatment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10041217A DE10041217A1 (de) 2000-08-22 2000-08-22 Verwendung von Dihydroboswelliasäuren oder hydrierten Extrakten aus Boswellia zur prophylaktischen und/oder therapeutischen Behandlung von unerwünschten körperlichen oder seelischen Zuständen
DE10041217.3 2000-08-22

Publications (1)

Publication Number Publication Date
WO2002015916A1 true WO2002015916A1 (fr) 2002-02-28

Family

ID=7653414

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/009315 WO2002015916A1 (fr) 2000-08-22 2001-08-11 Utilisation d'acides dihydroboswelliques ou d'extraits de boswellia hydrogenes en traitement preventif et/ou therapeutique

Country Status (3)

Country Link
AU (1) AU2001285885A1 (fr)
DE (1) DE10041217A1 (fr)
WO (1) WO2002015916A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011099029A1 (fr) 2010-02-15 2011-08-18 Laila Nutraceuticals Nouvel extrait de résine de gomme faiblement polaire de boswellia et ses compositions synergiques
US20120021077A1 (en) * 2007-07-18 2012-01-26 Bhushan Patwardhan Synergistic herbal composition for treatment of rheumatic and musculo-skeletal disorders (rmsds)
ITPD20120343A1 (it) * 2012-11-13 2014-05-14 Matteo Bevilacqua Composto in particolare per la cura della depressione e dell'ansia
US8828377B2 (en) 2010-03-15 2014-09-09 Laila Nutraceuticals Boswellia oil, its fractions and compositions for enhancing brain function
US9975917B1 (en) 2017-09-20 2018-05-22 King Saud University Pentacyclic triterpenoidal derivatives
CN114917751A (zh) * 2022-05-26 2022-08-19 杭州树派环保科技有限公司 一种高效甲醛清除剂及其制备方法
US11426438B2 (en) 2008-09-15 2022-08-30 Laila Nutraceuticals Method for treating arthritis with Boswellia serrata extracts

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10331750A1 (de) * 2003-07-14 2005-02-10 Keyneurotek Ag Verwendung der Hydrierungsprodukte von Weihrauch (Olibanum) zur Prophylaxe und/oder Behandlung von zerebraler Ischämie, Schädel/Hirntrauma und/oder Alzheimer-Krankheit

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04288095A (ja) * 1991-01-22 1992-10-13 Tsumura & Co 補体活性抑制剤
EP0552657A1 (fr) * 1992-01-24 1993-07-28 AMMON, Hermann P.T. Utilisation de l'acide boswellique pur
WO1997007796A1 (fr) * 1995-08-23 1997-03-06 Ammon Hermann P T Utilisation d'acide de boswell et de ses derives pour inhiber l'activite normale ou accrue de l'elastase leucocytaire ou de la plasmine
WO2000059523A1 (fr) * 1999-04-08 2000-10-12 Metagenics, Inc. Composition et procede destines au traitement de l'inflammation et des douleurs chez les mammiferes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943434A (en) * 1987-10-06 1990-07-24 Rohm And Haas Company Insecticidal hydrogenated neem extracts
US5629351A (en) * 1995-04-13 1997-05-13 Council Of Scientific & Industrial Research Boswellic acid compositions and preparation thereof
US6124362A (en) * 1998-07-17 2000-09-26 The Procter & Gamble Company Method for regulating hair growth

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04288095A (ja) * 1991-01-22 1992-10-13 Tsumura & Co 補体活性抑制剤
EP0552657A1 (fr) * 1992-01-24 1993-07-28 AMMON, Hermann P.T. Utilisation de l'acide boswellique pur
WO1997007796A1 (fr) * 1995-08-23 1997-03-06 Ammon Hermann P T Utilisation d'acide de boswell et de ses derives pour inhiber l'activite normale ou accrue de l'elastase leucocytaire ou de la plasmine
WO2000059523A1 (fr) * 1999-04-08 2000-10-12 Metagenics, Inc. Composition et procede destines au traitement de l'inflammation et des douleurs chez les mammiferes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN vol. 017, no. 100 (C - 1030) 26 February 1993 (1993-02-26) *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120021077A1 (en) * 2007-07-18 2012-01-26 Bhushan Patwardhan Synergistic herbal composition for treatment of rheumatic and musculo-skeletal disorders (rmsds)
US10286023B2 (en) 2008-09-15 2019-05-14 Laila Nutraceuticals Compositions comprising non-acidic Boswellia oil fraction as a bio-enhancer for enhancing bioavailability of biological agents
US11426438B2 (en) 2008-09-15 2022-08-30 Laila Nutraceuticals Method for treating arthritis with Boswellia serrata extracts
WO2011099029A1 (fr) 2010-02-15 2011-08-18 Laila Nutraceuticals Nouvel extrait de résine de gomme faiblement polaire de boswellia et ses compositions synergiques
US8551496B2 (en) 2010-02-15 2013-10-08 Laila Nutraceuticals Boswellia low polar gum resin extract and its synergistic compositions
US8828377B2 (en) 2010-03-15 2014-09-09 Laila Nutraceuticals Boswellia oil, its fractions and compositions for enhancing brain function
US9795646B2 (en) 2010-03-15 2017-10-24 Laila Nutraceuticals Boswellia oil, its fractions and compositions for enhancing brain function
ITPD20120343A1 (it) * 2012-11-13 2014-05-14 Matteo Bevilacqua Composto in particolare per la cura della depressione e dell'ansia
WO2014076643A1 (fr) * 2012-11-13 2014-05-22 ZAGGIA, Guerrino Composé particulièrement utile pour le traitement de la dépression et de l'anxiété
US9975917B1 (en) 2017-09-20 2018-05-22 King Saud University Pentacyclic triterpenoidal derivatives
CN114917751A (zh) * 2022-05-26 2022-08-19 杭州树派环保科技有限公司 一种高效甲醛清除剂及其制备方法

Also Published As

Publication number Publication date
AU2001285885A1 (en) 2002-03-04
DE10041217A1 (de) 2002-03-14

Similar Documents

Publication Publication Date Title
EP1453473B1 (fr) Emollients et compositions cosmetiques comprenant un diester de 2-methyl-1,3-propanediol
WO2003033634A1 (fr) Opacifiants de faible viscosite, exempts de tensioactifs anioniques
JP2004501175A (ja) イヌリンおよびイヌリン誘導体の使用
WO2001078675A1 (fr) Utilisation de matieres naturelles pour produire des preparations cosmetiques
WO2001072264A2 (fr) Preparations encapsulees dans des proliposomes (iv)
WO2001056541A1 (fr) Preparations cosmetiques contenant des extraits de waltheria indica
DE19911056B4 (de) Kosmetische Zubereitungen und deren Verwendung
EP1255525B1 (fr) Produit a lustre nacre
WO2000054741A1 (fr) UTILISATION DE β-(1,3)-GLUCANES NANOMETRIQUES HYDROSOLUBLES
EP1239814A2 (fr) Utilisation de residus de la fabrication du vin
EP1511706A1 (fr) Preparations a base d'alcool linoleique conjugue
WO2002015916A1 (fr) Utilisation d'acides dihydroboswelliques ou d'extraits de boswellia hydrogenes en traitement preventif et/ou therapeutique
EP1472211A1 (fr) Emollients et compositions cosmetiques
JP4768183B2 (ja) 不飽和の分枝エステルオイルの製造方法
WO2000078272A2 (fr) Alcools de guerbet
EP1235546A1 (fr) Utilisation de cires nanometriques
WO2001052809A1 (fr) Preparations cosmetiques ou pharmaceutiques contenant une quantite efficace d'un extrait d'arrabidaea chica
WO2001006995A1 (fr) Produits cosmetiques contenant de l'hydroxychavicole
WO2001043715A1 (fr) Procede de traitement cosmetique de la peau humaine
EP1620067A1 (fr) Preparations cosmetiques et/ou pharmaceutiques
DE19927653C2 (de) Wäßrige Perlglanzkonzentrate
EP1309311A2 (fr) Preparations cosmetiques contenant des acides dicarboxyliques
EP1094998A1 (fr) Procede de preparation de phytosqualane
DE202014100736U1 (de) Kosmetische oder pharmazeutische Zubereitungen zur Prävention und Behandlung der Cellulite
EP1083217A2 (fr) Agent épaississant

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BG BR BY CA CN CZ DZ HU ID IL IN JP KR MX NO NZ PL RO RU SG SI SK UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP